Crossmark

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study

Crossref DOI link: https://doi.org/10.1136/bmjresp-2022-001549

Published Online: 2023-09-20

Published Print: 2023-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Wang, Wen https://orcid.org/0009-0000-6672-9230
Li, Jieying

Zou, Congying

Zhao, Lifang

Zhu, Ya

Guo, Yue

Wang, Feiran
Funding

Funding for this research was provided by:

Beijing Natural Science Foundation of China (7192069)
License Information

License valid from 2023-09-21